Twenty years of triptans in the United States Medicaid programs: Utilization and reimbursement trends from 1993 to 2013

摘要

Objective After sumatriptan was approved by the Food and Drug Administration in 1992, triptans became first-line anti-migraine therapies. Rapidly rising triptan expenditures, however, led payers, including Medicaid, to implement cost-containment policies. We describe triptan utilization and reimbursement trends in Medicaid.